THERAPY DOSSIER · th-685061bf9203

Bee venom phospholipase A2 (bvPLA2)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02364349 ↗PHASE1completed

A Comparative Study on Local Allergic Responses of Bee Venom and Essential Bee Venom Pharmacopuncture

Healthy Volunteers

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27144583 ↗2016Reported benefit

Regulatory T Cells Contribute to the Inhibition of Radiation-Induced Acute Lung Inflammation via Bee Venom Phospholipase A2 in Mice.

MouseRadiationC57BL/6Femalen = 7 to 10 per group in the main experiment; 5 per group in th…Intraperitoneal0.2 mg/kg body weightFirst dose on day 7 after irradiation

Model: Focal irradiation of the left lung with a single 75 Gy fraction of X-rays (X-RAD 320, 3 mm collimator)

bvPLA2 reduced immune cell accumulation, inflammatory and fibrotic gene expression and histological lung damage after thoracic irradiation, and the effect was abolished by regulatory T cell depletion.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…